Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events
... this meta-analysis are based on a relatively small number of events, so they should be interpreted with caution. However, these findings provide evidence that long-acting -agonists are associated with significant risk, even when used with concomitant inhaled corticosteroids. This is the first meta- ...
... this meta-analysis are based on a relatively small number of events, so they should be interpreted with caution. However, these findings provide evidence that long-acting -agonists are associated with significant risk, even when used with concomitant inhaled corticosteroids. This is the first meta- ...
Six-Year Perspectives on the Safety and Tolerability of Nefazodone
... In Table 1, adverse experiences that occurred at an incidence of 5% or higher and were significantly more common in nefazodone recipients than in placebo recipients are enumerated.3 These findings reflect specific conditions existing at the time of each study and thus may not be useful to predict th ...
... In Table 1, adverse experiences that occurred at an incidence of 5% or higher and were significantly more common in nefazodone recipients than in placebo recipients are enumerated.3 These findings reflect specific conditions existing at the time of each study and thus may not be useful to predict th ...
Modafinil Bluefish Tablet ENG SmPC
... There are limited data available on the use of modafinil in older patients. In view of the potential for lower clearance and increased systemic exposure, it is recommended that patients over 65 years of age commence therapy at 100 mg daily. Paediatric population Modafinil should not be used in child ...
... There are limited data available on the use of modafinil in older patients. In view of the potential for lower clearance and increased systemic exposure, it is recommended that patients over 65 years of age commence therapy at 100 mg daily. Paediatric population Modafinil should not be used in child ...
International Consensus Report on Diagnosis and Treatment of
... and monitor the variable nature of this chronic disease and take appropriate actions to maintain control of asthma. The first (Green Zone) reflects therapy required to achieve the goals of therapy, i.e., maintain control of symptoms and prevent exacerbations. The step-wise approach described above i ...
... and monitor the variable nature of this chronic disease and take appropriate actions to maintain control of asthma. The first (Green Zone) reflects therapy required to achieve the goals of therapy, i.e., maintain control of symptoms and prevent exacerbations. The step-wise approach described above i ...
diclofenac - Endo Pharmaceuticals
... diclofenac treatment. In a large, open-label, controlled trial of 3,700 patients treated for 2-6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST occurred in about 4% of patients and included marked elevatio ...
... diclofenac treatment. In a large, open-label, controlled trial of 3,700 patients treated for 2-6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST occurred in about 4% of patients and included marked elevatio ...
Table of Contents - American Association of Clinical Endocrinologists
... in patients with non-functional adrenal tumors and functional adrenal tumors compared to healthy controls (p<0.001). In addition, MMP-9 levels of patients with functional adrenal tumors were significantly higher than those with non-functional adrenal tumors (p=0.002). After the surgical operation MM ...
... in patients with non-functional adrenal tumors and functional adrenal tumors compared to healthy controls (p<0.001). In addition, MMP-9 levels of patients with functional adrenal tumors were significantly higher than those with non-functional adrenal tumors (p=0.002). After the surgical operation MM ...
5 Hypertension PREP
... Subsequently, a 24-hour ambulatory blood pressure monitor (ABPM) reveals that 35% of the daytime readings exceed the 95th percentile for age, sex, and height, confirming the diagnosis of hypertension. Echocardiography reveals mild left ventricular hypertrophy (LVH), but otherwise shows normal result ...
... Subsequently, a 24-hour ambulatory blood pressure monitor (ABPM) reveals that 35% of the daytime readings exceed the 95th percentile for age, sex, and height, confirming the diagnosis of hypertension. Echocardiography reveals mild left ventricular hypertrophy (LVH), but otherwise shows normal result ...
Omitted and Delayed Medicines
... Omitted and Delayed Medicines A collaborative audit of omitted and delayed anti-microbial doses in acute, community and ...
... Omitted and Delayed Medicines A collaborative audit of omitted and delayed anti-microbial doses in acute, community and ...
Western Regional Meeting Abstracts
... in first-degree family members. It is well known that children with autism have an array of communication deficits, including phonology, semantics, syntax, and pragmatics. The overall aim of this project was to better understand verbal language use in individuals with ASD and their family members. Met ...
... in first-degree family members. It is well known that children with autism have an array of communication deficits, including phonology, semantics, syntax, and pragmatics. The overall aim of this project was to better understand verbal language use in individuals with ASD and their family members. Met ...
Non-Surgical guidelines for lung cancer
... In the UK, the National Institute for Health and Clinical Excellence (NICE) guidelines suggest that continuous hyperfractionated accelerated radiotherapy (CHART) or its radiobiological equivalent should be used, following the study by Saunders et al. [11], which showed a 2-year survival of 29% with ...
... In the UK, the National Institute for Health and Clinical Excellence (NICE) guidelines suggest that continuous hyperfractionated accelerated radiotherapy (CHART) or its radiobiological equivalent should be used, following the study by Saunders et al. [11], which showed a 2-year survival of 29% with ...
Arrow - Citalopram
... SSRIs (and venlafaxine) compared to those treated with placebo. Consequently, citalopram should not be used in children and adolescents less than 18 years of age. Clinical worsening and suicide risk Patients of any age with major depressive disorder may experience worsening of their depression and/o ...
... SSRIs (and venlafaxine) compared to those treated with placebo. Consequently, citalopram should not be used in children and adolescents less than 18 years of age. Clinical worsening and suicide risk Patients of any age with major depressive disorder may experience worsening of their depression and/o ...
Pharmacological Treatment of Postoperative Shivering: A
... 2.87; 95% CI, 0.31–26.4). Other adverse effects, reported in no more than one trial, were nausea or vomiting with fentanyl (34), and bradycardia with clonidine or ketanserin (39). ...
... 2.87; 95% CI, 0.31–26.4). Other adverse effects, reported in no more than one trial, were nausea or vomiting with fentanyl (34), and bradycardia with clonidine or ketanserin (39). ...
Sandostatin, Sandostatin Lar Depot (Octreotide Acetate)
... overall decrease in average chest tube output after 3 days of therapy. However, in two patients (29%) the chylothoraces ultimately resolved during the octreotide infusion. Treatment was well tolerated, and no serious side effects were noted. In contrast to previously published reports, the author fo ...
... overall decrease in average chest tube output after 3 days of therapy. However, in two patients (29%) the chylothoraces ultimately resolved during the octreotide infusion. Treatment was well tolerated, and no serious side effects were noted. In contrast to previously published reports, the author fo ...
retreatment of persons in whom prior therapy has failed
... (Expansions and notes for abbreviations used in this section can be found in Methods Table 3. A summary of recommendations for retreatment is found in the box.) This section provides guidance on the retreatment of a person with chronic HCV infection in whom prior therapy has failed. The level of the ...
... (Expansions and notes for abbreviations used in this section can be found in Methods Table 3. A summary of recommendations for retreatment is found in the box.) This section provides guidance on the retreatment of a person with chronic HCV infection in whom prior therapy has failed. The level of the ...
Didanosine - WHO archives - World Health Organization
... treatment. A prospective observational cohort study was undertaken to assess the feasibility, effectiveness, adherence, toxicity and viral resistance of antiretroviral therapy. The clinical and biological results of the study were comparable to those seen in western cohorts, despite differences in H ...
... treatment. A prospective observational cohort study was undertaken to assess the feasibility, effectiveness, adherence, toxicity and viral resistance of antiretroviral therapy. The clinical and biological results of the study were comparable to those seen in western cohorts, despite differences in H ...
Why test for Hydrocodone and Hydromorphone?
... according to the Drug Enforcement Administration (1). It is a semi-synthetic opioid, most commonly known as Vicodin® and is prescribed as a cough suppressant and for the treatment of moderate to severe pain. One of its metabolites, hydromorphone, is considered to be more potent than the parent drug, ...
... according to the Drug Enforcement Administration (1). It is a semi-synthetic opioid, most commonly known as Vicodin® and is prescribed as a cough suppressant and for the treatment of moderate to severe pain. One of its metabolites, hydromorphone, is considered to be more potent than the parent drug, ...
MabThera : EPAR - Product Information - EMA
... Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells such as patients with CLL, who may be at higher risk of especially severe cytokine release syndrome, ...
... Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells such as patients with CLL, who may be at higher risk of especially severe cytokine release syndrome, ...
Protocol S1.
... hospitalized patients. This PCR assay is, however, potentially affected by mecA deletion from SCCmec elements (false-positive signal from MSSA strains) and divergent sequence variants in SCCmec (false-negative signal from MRSA strains). Validation studies on international S.aureus strain collections ...
... hospitalized patients. This PCR assay is, however, potentially affected by mecA deletion from SCCmec elements (false-positive signal from MSSA strains) and divergent sequence variants in SCCmec (false-negative signal from MRSA strains). Validation studies on international S.aureus strain collections ...
Effect of Short-term Treatment With Gaboxadol on Sleep
... no effects on, or suppressing, slow wave sleep (SWS, stages 3 and 4) and slow wave activity (SWA) as measured with power spectral analysis.1-5 Furthermore, for some of these agents, problems may arise either during or after the course of treatment due to next-day residual effects (hangover), develop ...
... no effects on, or suppressing, slow wave sleep (SWS, stages 3 and 4) and slow wave activity (SWA) as measured with power spectral analysis.1-5 Furthermore, for some of these agents, problems may arise either during or after the course of treatment due to next-day residual effects (hangover), develop ...
ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease
... When citing this document, the American College of Cardiology and the American Heart Association recommend that the following format be used: Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O’Gara PT, O’Rourke RA, Rahimtoola SH. ACC/AHA ...
... When citing this document, the American College of Cardiology and the American Heart Association recommend that the following format be used: Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O’Gara PT, O’Rourke RA, Rahimtoola SH. ACC/AHA ...
American Thoracic Society European Respiratory Society 61 Broadway New York, NY 10006-2755
... without obvious fibrosis [2]. ...
... without obvious fibrosis [2]. ...
Thesis 15th May 2012 - Portsmouth Research Portal
... CF is a lethal, autosomal recessive, multisystem disease primarily affecting the organs of epithelial origin (Coakley & Boucher, 2007) with the respiratory system being the major cause for morbity and mortality. It is the result of mutations affecting the gene which encodes for a chloride channel kn ...
... CF is a lethal, autosomal recessive, multisystem disease primarily affecting the organs of epithelial origin (Coakley & Boucher, 2007) with the respiratory system being the major cause for morbity and mortality. It is the result of mutations affecting the gene which encodes for a chloride channel kn ...